Novo Nordisk A/s

Kristian Tage Hansen

Peter Faarup

Louis B Hansen

Yi Wang

Xiang Gao

Hongtao Guan

Henning Thoegersen

Lars Fogh Iversen

Erling Guddal

Erik B Nielsen

Kristian Sass-Oerum

Peter H Andersen

Sebastian Beck Joergensen

Per Noergaard

Xujia Zhang

Frederik Gronwald

Per Sauerberg

Svend Ludvigsen

Lars Bohn Hansen

Birgit Wieczorek

Liselotte Bjerre Knudsen

Morten Schlein

Dorthe Kot Engelund

Kilian Waldemar Conde Frieboes

Hans Bundgaard

Lotte Bjerre Knudsen

Johan Selmer

Claude Bonde

Tine Elisabeth Gottschalk Bøving

Ejvind Jensen

Lars Hansen

Tine Elisabeth Gottschalk Boving

The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein said extension consists of 3 to 36 amino acid residues and where the compound has a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

MIC-1 compounds and use thereof

The invention relates to MIC-1 compounds. More specifically it relates to compounds comprising a MIC-1 polypeptide with an N-terminal amino acid extension and a protractor wherein the amino acid extension comprises 3 to 36 amino acid residues and where the MIC-1 polypeptide and the N-terminal amino acid extension together have a calculated pI lower than 6.5. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.

MIC-1 compounds and uses thereof

Pharmaceutical composition for parenteral administration comprising a meal related insulin peptide and an insulinotropic peptide.

Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia

Use of medicament for life saving treatment of critically ill patients and method of treatment. The medicament comprises a GLP-1 compound which effectively controls the blood glucose level.

Use of GLP-1 compound for treatment of critically ill patients

The present invention relates to a novel method for treating a mammal suffering from hypercholesterolemia and related disorders.

Method of treating hypercholesterolemia and related disorders

Novel 2, 3, 4, 5-tetrahydro-1H-3-benzazepines, which in the 7-position have a methoxymethyloxy group, in the 8-position hydrogen, halogen, or a nitro group and in the 5-position have an optionally substituted phenyl ortho-fused ring-system, with interesting effects on the central nervous system.

Benzazepines

Novel 2,3,4,5-tetrahydro-1H-3-benzazepines having the formula ##STR1## wherein R.sup.3 represents H, C.sub.1-3 -alkyl or C.sub.3-7 -cycloalkyl;

Novel benzazepine derivatives

Compounds having the formula ##STR1## wherein R.sup.1, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are hydrogen or a substituent, R.sup.2 is a substituent, R.sup.5 is an optionally-substituted bicyclic ring system, especially a 7-benzofuranyl or 2,3-dihydrobenzofuran-7-yl substituent, R.sup.9 is hydrogen, alkyl, alkoxycarbonyl or, together with R.sup.8, forms the remainder of a heterocyclic ring, their pharmaceutically-accceptable salts, as well as their pharmaceutical compositions and use as prodrugs for compounds active for the treatment of mental disorders, are disclosed.

Carbamic acid ester of substituted

Novel 2,3,4,5-tetrahydro-1H-3-benzazepines having the formula ##STR1## wherein R.sup.3 represents H, C.sub.1-3 -alkyl or C.sub.3-7 -cycloalkyl; R.sup.4 represents hydrogen or R.sup.4 together with R.sup.10 represents a bridge which connects the positions to which R.sup.4 and R.sup.10 are linked, said bridge being --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, --O--CH.sub.2 -- or --S--CH.sub.2 --;

Growing community of inventors

Slangerup, Denmark

Kristian Tage Hansen